Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Lorazepam
Form:
21 of 21 products shown
9 general benefit · 2 Limited Use · 10 not a benefit
Apo-Lorazepam · DIN 00655740 · 0.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Lorazepam · DIN 00655740
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1985-12-31 · brand APO-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Apotex inc · schedule Targeted substances (cdsa iv)
Apo-Lorazepam: Formulary list price $0.04 per unit (the source does not state the unit; exact figure $0.0359). What the ministry pays, not the patient.
Ministry pays: $0.0359 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00655740: Apo-Lorazepam
Raw flags: sec3=Y
Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id APX
Source form: Tab; strength: 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.0359; ministry $0.0359
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00655740
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6295Interchangeable products
Ativan · DIN 02041413 · not recorded
PMS-Lorazepam · DIN 00728187 · $0.0359
Teva-Lorazepam · DIN 00711101 · $0.0359
Shortage status: resolved shortage (ended April 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00655740
Shortage record checked October 6, 2026
PMS-Lorazepam · DIN 00728187 · 0.5 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Lorazepam · DIN 00728187
Manufacturer: Pharmascience Inc.; listing date 2002-04-04
Health Canada: Marketed since 1988-12-31 · brand PMS-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Pharmascience inc · schedule Targeted substances (cdsa iv)
PMS-Lorazepam: Formulary list price $0.04 per unit (the source does not state the unit; exact figure $0.0359). What the ministry pays, not the patient.
Ministry pays: $0.0359 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00728187: PMS-Lorazepam
Raw flags: sec3=Y
Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id PMS
Source form: Tab; strength: 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.0359; ministry $0.0359
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00728187
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9349Interchangeable products
Apo-Lorazepam · DIN 00655740 · $0.0359
Ativan · DIN 02041413 · not recorded
Teva-Lorazepam · DIN 00711101 · $0.0359
Shortage status: resolved shortage (ended March 20, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00728187
Shortage record checked October 6, 2026
Teva-Lorazepam · DIN 00711101 · 0.5 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Lorazepam · DIN 00711101
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2014-01-11 · brand TEVA-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)
Teva-Lorazepam: Formulary list price $0.04 per unit (the source does not state the unit; exact figure $0.0359). What the ministry pays, not the patient.
Ministry pays: $0.0359 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00711101: Teva-Lorazepam
Raw flags: sec3=Y
Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id TEV
Source form: Tab; strength: 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.0359; ministry $0.0359
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00711101
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7314Interchangeable products
Apo-Lorazepam · DIN 00655740 · $0.0359
Ativan · DIN 02041413 · not recorded
PMS-Lorazepam · DIN 00728187 · $0.0359
Shortage status: resolved shortage (ended July 2, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00711101
Shortage record checked October 6, 2026
Apo-Lorazepam · DIN 00655759 · 1 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Lorazepam · DIN 00655759
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1985-12-31 · brand APO-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Apotex inc · schedule Targeted substances (cdsa iv)
Apo-Lorazepam: Formulary list price $0.04 per unit (the source does not state the unit; exact figure $0.0447). What the ministry pays, not the patient.
Ministry pays: $0.0447 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00655759: Apo-Lorazepam
Raw flags: sec3=Y
Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id APX
Source form: Tab; strength: 1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0447; ministry $0.0447
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00655759
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6296Interchangeable products
Ativan · DIN 02041421 · not recorded
PMS-Lorazepam · DIN 00728195 · $0.0447
Teva-Lorazepam · DIN 00637742 · $0.0447
Shortage status: resolved shortage (ended September 19, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00655759
Shortage record checked October 6, 2026
PMS-Lorazepam · DIN 00728195 · 1 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Lorazepam · DIN 00728195
Manufacturer: Pharmascience Inc.; listing date 2002-04-04
Health Canada: Marketed since 1988-12-31 · brand PMS-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Pharmascience inc · schedule Targeted substances (cdsa iv)
PMS-Lorazepam: Formulary list price $0.04 per unit (the source does not state the unit; exact figure $0.0447). What the ministry pays, not the patient.
Ministry pays: $0.0447 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00728195: PMS-Lorazepam
Raw flags: sec3=Y
Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id PMS
Source form: Tab; strength: 1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0447; ministry $0.0447
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00728195
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9423Interchangeable products
Apo-Lorazepam · DIN 00655759 · $0.0447
Ativan · DIN 02041421 · not recorded
Teva-Lorazepam · DIN 00637742 · $0.0447
Shortage status: discontinued (June 15, 2020, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00728195
Shortage record checked October 6, 2026
Teva-Lorazepam · DIN 00637742 · 1 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Lorazepam · DIN 00637742
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2014-01-11 · brand TEVA-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)
Teva-Lorazepam: Formulary list price $0.04 per unit (the source does not state the unit; exact figure $0.0447). What the ministry pays, not the patient.
Ministry pays: $0.0447 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00637742: Teva-Lorazepam
Raw flags: sec3=Y
Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id TEV
Source form: Tab; strength: 1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0447; ministry $0.0447
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00637742
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6135Interchangeable products
Apo-Lorazepam · DIN 00655759 · $0.0447
Ativan · DIN 02041421 · not recorded
PMS-Lorazepam · DIN 00728195 · $0.0447
Shortage status: resolved shortage (ended February 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00637742
Shortage record checked October 6, 2026
Apo-Lorazepam · DIN 00655767 · 2 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Lorazepam · DIN 00655767
Manufacturer: Apotex Inc.; listing date 1996-10-01
Health Canada: Marketed since 1985-12-31 · brand APO-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Apotex inc · schedule Targeted substances (cdsa iv)
Apo-Lorazepam: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0699). What the ministry pays, not the patient.
Ministry pays: $0.0699 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00655767: Apo-Lorazepam
Raw flags: sec3=Y
Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id APX
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.0699; ministry $0.0699
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00655767
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6297Interchangeable products
Ativan · DIN 02041448 · not recorded
PMS-Lorazepam · DIN 00728209 · $0.0699
Teva-Lorazepam · DIN 00637750 · $0.0699
Shortage status: resolved shortage (ended May 9, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00655767
Shortage record checked October 6, 2026
PMS-Lorazepam · DIN 00728209 · 2 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Lorazepam · DIN 00728209
Manufacturer: Pharmascience Inc.; listing date 2002-04-04
Health Canada: Marketed since 1988-12-31 · brand PMS-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Pharmascience inc · schedule Targeted substances (cdsa iv)
PMS-Lorazepam: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0699). What the ministry pays, not the patient.
Ministry pays: $0.0699 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00728209: PMS-Lorazepam
Raw flags: sec3=Y
Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id PMS
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.0699; ministry $0.0699
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00728209
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9424Interchangeable products
Apo-Lorazepam · DIN 00655767 · $0.0699
Ativan · DIN 02041448 · not recorded
Teva-Lorazepam · DIN 00637750 · $0.0699
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00728209
Shortage record checked October 6, 2026
Teva-Lorazepam · DIN 00637750 · 2 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Lorazepam · DIN 00637750
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2014-01-11 · brand TEVA-LORAZEPAM · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Teva canada limited · schedule Targeted substances (cdsa iv)
Teva-Lorazepam: Formulary list price $0.07 per unit (the source does not state the unit; exact figure $0.0699). What the ministry pays, not the patient.
Ministry pays: $0.0699 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00637750: Teva-Lorazepam
Raw flags: sec3=Y
Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id TEV
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.0699; ministry $0.0699
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00637750
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6136Interchangeable products
Apo-Lorazepam · DIN 00655767 · $0.0699
Ativan · DIN 02041448 · not recorded
PMS-Lorazepam · DIN 00728209 · $0.0699
Shortage status: resolved shortage (ended March 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00637750
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Lorazepam Injection USP · DIN 02243278
Manufacturer: Sandoz Canada Inc.; listing date 2017-02-28
Health Canada: Marketed since 2005-09-21 · brand LORAZEPAM INJECTION USP · ATC N05BA06 LORAZEPAM · form Solution · route Intramuscular, Intravenous · ingredients LORAZEPAM 4 MG/ML · company Sandoz canada incorporated · schedule Targeted substances (cdsa iv)
Lorazepam Injection USP: Formulary list price $19.08 per unit (the source does not state the unit; exact figure $19.0800). What the ministry pays, not the patient.
Ministry pays: $19.0800 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02243278: Lorazepam Injection USP
Raw flags: sec12=Y, sec3=Y
Item: 282400076; group id 522; item number 1412; lccId 00275; manufacturer id SDZ
Source form: Inj Sol (with preservative); strength: 4mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $19.0800; ministry $19.0800
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243278
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67176Interchangeable products
Ativan · DIN 02041405 · not recorded
Lorazepam Injection, USP · DIN 02550962 · $19.0800
Shortage status: resolved shortage (ended June 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243278
Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Lorazepam Injection, USP · DIN 02550962
Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2026-01-30
Health Canada: Marketed since 2026-01-20 · brand LORAZEPAM INJECTION, USP · ATC N05BA06 LORAZEPAM · form Solution · route Intramuscular, Intravenous · ingredients LORAZEPAM 4 MG/ML · company Fresenius kabi canada ltd · schedule Targeted substances (cdsa iv)
Lorazepam Injection, USP: Formulary list price $19.08 per unit (the source does not state the unit; exact figure $19.0800). What the ministry pays, not the patient.
Ministry pays: $19.0800 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02550962: Lorazepam Injection, USP
Raw flags: sec12=Y, sec3=Y
Item: 282400076; group id 522; item number 1412; lccId 00275; manufacturer id FKC
Source form: Inj Sol (with preservative); strength: 4mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $19.0800; ministry $19.0800
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02550962
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103972Interchangeable products
Ativan · DIN 02041405 · not recorded
Lorazepam Injection USP · DIN 02243278 · $19.0800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02550962
DIN 02410745: Lorazepam Sublingual
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400078; group id 523; item number 1413; lccId None; manufacturer id AAP
Source form: SL Tab; strength: 0.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.1099; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02410745
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89541Interchangeable products
Ativan · DIN 02041456 · not recorded
Shortage status: anticipated shortage (last updated September 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02410745
DIN 02410753: Lorazepam Sublingual
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400169; group id 523; item number 1414; lccId None; manufacturer id AAP
Source form: SL Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.1385; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02410753
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89542Interchangeable products
Ativan · DIN 02041464 · not recorded
Shortage status: anticipated shortage (last updated September 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02410753
DIN 02410761: Lorazepam Sublingual
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400079; group id 523; item number 1415; lccId None; manufacturer id AAP
Source form: SL Tab; strength: 2mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.2152; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02410761
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89543Interchangeable products
Ativan · DIN 02041472 · not recorded
Shortage status: anticipated shortage (last updated September 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02410761
Shortage record checked October 6, 2026
Ativan · DIN 02041456 · 0.5 mg · SL tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.Discontinued July 3, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ativan · DIN 02041456
Manufacturer: Pfizer Canada Inc.; listing date 2013-10-31
Health Canada: Cancelled post market since 2026-07-03 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 0.5 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
DIN 02041456: Ativan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400078; group id 523; item number 1413; lccId None; manufacturer id PFI
Source form: SL Tab; strength: 0.5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02041456
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17817Interchangeable products
Lorazepam Sublingual · DIN 02410745 · not recorded
Shortage status: discontinued (February 27, 2026, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041456
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 3, 2026 — choose a marketed DIN from the same-category list.
Ativan · DIN 02041413 · 0.5 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.Discontinued November 5, 2025 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ativan · DIN 02041413
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-11-05 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 0.5 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
DIN 02041413: Ativan
Raw flags: notABenefit=Y, sec3=Y
Item: 281608136; group id 495; item number 1269; lccId None; manufacturer id PFI
Source form: Tab; strength: 0.5mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02041413
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16589Interchangeable products
Apo-Lorazepam · DIN 00655740 · $0.0359
PMS-Lorazepam · DIN 00728187 · $0.0359
Teva-Lorazepam · DIN 00711101 · $0.0359
Shortage status: discontinued (October 31, 2025, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041413
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 5, 2025 — choose a marketed DIN from the same-category list.
Ativan · DIN 02041464 · 1 mg · SL tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.Discontinued July 3, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-07-03 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ativan · DIN 02041464
Manufacturer: Pfizer Canada Inc.; listing date 2013-10-31
Health Canada: Cancelled post market since 2026-07-03 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 1 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
DIN 02041464: Ativan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400169; group id 523; item number 1414; lccId None; manufacturer id PFI
Source form: SL Tab; strength: 1mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02041464
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16118Interchangeable products
Lorazepam Sublingual · DIN 02410753 · not recorded
Shortage status: discontinued (February 27, 2026, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041464
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 3, 2026 — choose a marketed DIN from the same-category list.
Ativan · DIN 02041421 · 1 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.Discontinued November 5, 2025 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ativan · DIN 02041421
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-11-05 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 1 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
DIN 02041421: Ativan
Raw flags: notABenefit=Y, sec3=Y
Item: 281608098; group id 495; item number 1270; lccId None; manufacturer id PFI
Source form: Tab; strength: 1mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02041421
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16588Interchangeable products
Apo-Lorazepam · DIN 00655759 · $0.0447
PMS-Lorazepam · DIN 00728195 · $0.0447
Teva-Lorazepam · DIN 00637742 · $0.0447
Shortage status: discontinued (October 31, 2025, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041421
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 5, 2025 — choose a marketed DIN from the same-category list.
Ativan · DIN 02041472 · 2 mg · SL tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-29 — choose a marketed DIN from the same-category list.Discontinued December 29, 2024 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2024-12-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-12-29 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ativan · DIN 02041472
Manufacturer: Pfizer Canada Inc.; listing date 2013-10-31
Health Canada: Cancelled post market since 2024-12-29 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Sublingual · ingredients LORAZEPAM 2 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
DIN 02041472: Ativan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 282400079; group id 523; item number 1415; lccId None; manufacturer id PFI
Source form: SL Tab; strength: 2mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02041472
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16586Interchangeable products
Lorazepam Sublingual · DIN 02410761 · not recorded
Shortage status: discontinued (October 31, 2025, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041472
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 29, 2024 — choose a marketed DIN from the same-category list.
Ativan · DIN 02041448 · 2 mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.Discontinued November 5, 2025 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-11-05 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Ativan · DIN 02041448
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2025-11-05 · brand ATIVAN · ATC N05BA06 LORAZEPAM · form Tablet · route Oral · ingredients LORAZEPAM 2 MG · company Pfizer canada ulc · schedule Targeted substances (cdsa iv)
DIN 02041448: Ativan
Raw flags: notABenefit=Y, sec3=Y
Item: 281608099; group id 495; item number 1271; lccId None; manufacturer id PFI
Source form: Tab; strength: 2mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02041448
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16587Interchangeable products
Apo-Lorazepam · DIN 00655767 · $0.0699
PMS-Lorazepam · DIN 00728209 · $0.0699
Teva-Lorazepam · DIN 00637750 · $0.0699
Shortage status: discontinued (October 31, 2025, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041448
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 5, 2025 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-01-19 — choose a marketed DIN from the same-category list.Discontinued January 19, 2005 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2005-01-19 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2005-01-19 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 481
Reason for Use code 481
For the management of patients receiving palliative care*.
Coverage limit:
LU Authorization Period: 1 year
Coverage limit:
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Ativan · DIN 02041405
Manufacturer: Wyeth Pharmaceuticals; listing date 2017-02-28
Health Canada: Cancelled post market since 2005-01-19 · brand ATIVAN INJECTION LIQ 4MG/ML · ATC N05BA06 LORAZEPAM · form Solution · route Intravenous, Intramuscular · ingredients LORAZEPAM 4 MG/ML · company Wyeth canada · schedule Targeted substances (cdsa iv)
DIN 02041405: Ativan
Raw flags: notABenefit=Y, sec3=Y
Item: 282400076; group id 522; item number 1412; lccId 00275; manufacturer id WAY
Source form: Inj Sol (with preservative); strength: 4mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02041405
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15616Interchangeable products
Lorazepam Injection USP · DIN 02243278 · $19.0800
Lorazepam Injection, USP · DIN 02550962 · $19.0800
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041405
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 19, 2005 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (N05BA): coverage varies; not interchangeable
Alprazolam (Xanax): general benefit, not a benefit
Bromazepam (Lectopam): general benefit, not a benefit
Chlordiazepoxide (Librium): general benefit, not a benefit
Clorazepate dipotassium (Tranxene): general benefit, not a benefit
Diazepam (Diazepam Injection USP): general benefit, limited Use 481, not a benefit
Oxazepam (Apo-Oxazepam): general benefit, not a benefit
2 more in the class list below
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered
Matched class: 28:16:08 Tranquilizers
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE
Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE
28:16:08 Tranquilizers
· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:08
and 21 more
Other drugs in the same formulary class (28:24 Sedatives and Hypnotics) and how they are covered
Matched class: 28:24 Sedatives and Hypnotics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: NITRAZEPAM, PHENOBARBITAL, TEMAZEPAM
Some products covered without a code (check the product listing): BUSPIRONE HYDROCHLORIDE, FLURAZEPAM, METHOTRIMEPRAZINE, TRIAZOLAM
28:24 Sedatives and Hypnotics
· 40 products · Off-Formulary Interchangeable, not an ODB benefit (38), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2) · strengths: 3.75mg, 5mg, 7.5mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:24
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
OXAZEPAM · General benefit (3), Listed, not a benefit (3)
1 INDICATIONS
APO-OXAZEPAM (oxazepam tablets) is indicated for the short-term symptomatic relief of
excessive anxiety and tension in patients with anxiety neurosis.
PM: https://pdf.hres.ca/dpd_pm/00072522.PDF; date SEP 05, 2023; DIN 00402680; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS
TEVA-LORAZEPAM (lorazepam) is indicated for:
• the short-term relief of manifestations of excessive anxiety in patients with anxiety neurosis.
Anxiety and tension associated with the stresses of everyday life usually do not require
treatment with anxiolytic drugs.
1.1 Pediatrics
Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada
has not authorized an indication for pediatric use.
1.2 Geriatrics
Evidence from clinical studies and experience suggests that use in the geriatric population is
associated with differences in safety or effectiveness.
Long-term use of TEVA-LORAZEPAM should be avoided in geriatric patients. Enhanced
monitoring is recommended (see 7 WARNINGS AND PRECAUTIONS, Falls and fractures; 4
DOSAGE AND ADMINISTRATION, 4.1 Dosing considerations).
https://pdf.hres.ca/dpd_pm/00070208.PDF
PM date: March 05, 1985
Source product: TEVA-LORAZEPAM; DIN 00637742; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
PMS-Lorazepam · DIN 00728195
Shortage status: discontinued (2020-06-15, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00728195
Ativan · DIN 02041456
Shortage status: discontinued (2026-02-27, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041456
Ativan · DIN 02041413
Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041413
Ativan · DIN 02041464
Shortage status: discontinued (2026-02-27, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041464
Ativan · DIN 02041421
Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041421
Ativan · DIN 02041472
Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041472
Ativan · DIN 02041448
Shortage status: discontinued (2025-10-31, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02041448
For Lorazepam Sublingual, Ativan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.